• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝胆中心胆管癌错配。

Cholangiocarcinoma miscoding in hepatobiliary centres.

机构信息

Liver Unit, Division of Digestive Diseases, Imperial College London and Imperial College Healthcare NHS Trust, UK.

Aintree University Hospital Foundation Trust, UK.

出版信息

Eur J Surg Oncol. 2021 Mar;47(3 Pt B):635-639. doi: 10.1016/j.ejso.2020.09.039. Epub 2020 Oct 1.

DOI:10.1016/j.ejso.2020.09.039
PMID:33032867
Abstract

INTRODUCTION

Cholangiocarcinoma (CCA) are sub-divided into intrahepatic (iCCA) or extrahepatic (eCCA). eCCA are further subdivided into perihilar (pCCA) and distal (dCCA). Current and previous versions of the WHO International Coding of Disease and Oncology classifications (ICD) have separate topography codes for iCCA and eCCA, but none for pCCA. Over recent decades, multiple studies report rising incidence rates of iCCA with declining rates of eCCA, without reference to pCCA. We hypothesised the lack of a specific code for pCCA has led to errors CCA coding, specifically with miscoding of pCCA as iCCA.

METHODS

Clinical notes of cases coded as hepatobiliary carcinoma using ICD-10 criteria (C22.1/Intrahepatic Bile Duct carcinoma, C24.0/Extrahepatic Bile Duct carcinoma, C23X/Malignant Neoplasm Gall Bladder, C22.0/Malignant Neoplasm Liver Cell Carcinoma) over a 2 year period (2015-2017), were reviewed by two independent clinicians at three independent UK regional HepatoPancreatoBiliary centres. The agreed final diagnosis was compared to the originally allocated ICD-10 code.

RESULTS

Of the 625 CCA cases fully reviewed, 226 were coded as C22.1/iCCA. 98 (43%) of these were true iCCA and coded correctly, while 76 cases (34%) were actually pCCA. 92% all pCCA cases were incorrectly coded as iCCA.

CONCLUSION

CCA coding misclassification in UK HPB centres is common, particularly the miscoding of pCCA, which is extrahepatic and the commonest form of CCA, as iCCA. This may be contributing to apparent rising incidence rates of iCCA. Our findings confirm the need to implement distinct topographical codes for iCCA, pCCA and dCCA in future iterations of ICD.

摘要

简介

胆管癌(CCA)可分为肝内(iCCA)或肝外(eCCA)。eCCA 进一步分为肝门部(pCCA)和远端(dCCA)。世界卫生组织(WHO)国际疾病分类和肿瘤学分类(ICD)的现行和以前版本为 iCCA 和 eCCA 分别提供了单独的解剖学编码,但 pCCA 没有。最近几十年,多项研究报告称 iCCA 的发病率上升,而 eCCA 的发病率下降,而没有提到 pCCA。我们假设缺乏 pCCA 的特定编码导致了 CCA 编码错误,特别是将 pCCA 错误编码为 iCCA。

方法

在两年期间(2015-2017 年),使用 ICD-10 标准(C22.1/肝内胆管癌、C24.0/肝外胆管癌、C23X/胆囊恶性肿瘤、C22.0/肝细胞癌恶性肿瘤)对编码为肝胆癌的病例的临床记录进行了回顾,由三家英国区域肝胆胰中心的两位独立临床医生进行。将最终诊断与最初分配的 ICD-10 编码进行比较。

结果

在对 625 例 CCA 病例进行全面审查后,有 226 例被编码为 C22.1/iCCA。其中 98 例(43%)为真正的 iCCA,编码正确,而 76 例(34%)实际上为 pCCA。所有 pCCA 病例中有 92%被错误编码为 iCCA。

结论

英国 HPB 中心的 CCA 编码分类错误很常见,特别是 pCCA 的分类错误,因为 pCCA 是肝外的,也是最常见的 CCA 类型,被错误编码为 iCCA。这可能是 iCCA 发病率上升的原因之一。我们的发现证实了在 ICD 的未来迭代中为 iCCA、pCCA 和 dCCA 实施不同的解剖学编码的必要性。

相似文献

1
Cholangiocarcinoma miscoding in hepatobiliary centres.肝胆中心胆管癌错配。
Eur J Surg Oncol. 2021 Mar;47(3 Pt B):635-639. doi: 10.1016/j.ejso.2020.09.039. Epub 2020 Oct 1.
2
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.肝内和肝外胆管癌的危险因素:系统评价和荟萃分析。
J Hepatol. 2020 Jan;72(1):95-103. doi: 10.1016/j.jhep.2019.09.007. Epub 2019 Sep 16.
3
Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.德国胆管癌:流行病学趋势和分类错误的影响。
Liver Int. 2019 Feb;39(2):316-323. doi: 10.1111/liv.13954. Epub 2018 Oct 8.
4
Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.美国 2001 至 2017 年胆管癌发病率和死亡率的时间变化。
Oncologist. 2022 Oct 1;27(10):874-883. doi: 10.1093/oncolo/oyac150.
5
Clinical presentation, diagnosis and staging of cholangiocarcinoma.胆管癌的临床表现、诊断和分期。
Liver Int. 2019 May;39 Suppl 1:98-107. doi: 10.1111/liv.14086. Epub 2019 Mar 25.
6
Novel Targeted Therapies for Advanced Cholangiocarcinoma.晚期胆管癌的新型靶向治疗
Medicina (Kaunas). 2021 Feb 26;57(3):212. doi: 10.3390/medicina57030212.
7
Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?胆管癌发病率上升趋势:国际疾病分类系统是否在误导我们?
J Hepatol. 2012 Apr;56(4):848-54. doi: 10.1016/j.jhep.2011.11.015. Epub 2011 Dec 13.
8
Clinical treatment of cholangiocarcinoma: an updated comprehensive review.胆管癌的临床治疗:最新综合综述。
Ann Hepatol. 2022 Sep-Oct;27(5):100737. doi: 10.1016/j.aohep.2022.100737. Epub 2022 Jul 7.
9
Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma--focus on East and South-Eastern Asia.肝内胆管癌和肝外胆管癌发病率的比较——聚焦于东亚和东南亚地区。
Asian Pac J Cancer Prev. 2010;11(5):1159-66.
10
Pathologic classification of cholangiocarcinoma: New concepts.胆管癌的病理分类:新概念
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):277-93. doi: 10.1016/j.bpg.2015.02.006. Epub 2015 Feb 17.

引用本文的文献

1
Intrahepatic cholangiocarcinoma mortality in the USA, 1999-2020: a 21-year population-based analysis.1999 - 2020年美国肝内胆管癌死亡率:一项基于21年人口的分析。
Cancer Causes Control. 2025 Jul 24. doi: 10.1007/s10552-025-02038-8.
2
Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes.诊断编码和实验室检查用于识别胆管癌及其亚型的有效性。
Pharmacoepidemiol Drug Saf. 2025 May;34(5):e70154. doi: 10.1002/pds.70154.
3
Digestive cancers: mechanisms, therapeutics and management.消化系统癌症:机制、治疗方法与管理
Signal Transduct Target Ther. 2025 Jan 15;10(1):24. doi: 10.1038/s41392-024-02097-4.
4
Trends analysis of cancer incidence, mortality, and survival for the elderly in the United States, 1975-2020.美国老年人癌症发病率、死亡率和生存率的趋势分析,1975-2020 年。
Cancer Med. 2024 Aug;13(15):e70062. doi: 10.1002/cam4.70062.
5
Cholangiocarcinoma across England: Temporal changes in incidence, survival and routes to diagnosis by region and level of socioeconomic deprivation.全英格兰的胆管癌:发病率、生存率以及按地区和社会经济剥夺程度划分的诊断途径的时间变化。
JHEP Rep. 2023 Dec 15;6(3):100983. doi: 10.1016/j.jhepr.2023.100983. eCollection 2024 Mar.
6
British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma.英国胃肠病学会胆管癌诊断和管理指南。
Gut. 2023 Dec 7;73(1):16-46. doi: 10.1136/gutjnl-2023-330029.
7
Pushing the limits for the surgical treatment of intrahepatic cholangiocarcinoma.突破肝内胆管癌外科治疗的极限。
Hepatobiliary Surg Nutr. 2023 Feb 28;12(1):99-104. doi: 10.21037/hbsn-22-555. Epub 2023 Jan 9.
8
Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.美国 2001 至 2017 年胆管癌发病率和死亡率的时间变化。
Oncologist. 2022 Oct 1;27(10):874-883. doi: 10.1093/oncolo/oyac150.
9
The 11th revision of the International Statistical Classification of Disease and Related Health Problems and Cholangiocarcinoma.《国际疾病及相关健康问题统计分类》第11次修订版与胆管癌
Hepatobiliary Surg Nutr. 2022 Apr;11(2):276-279. doi: 10.21037/hbsn-22-69.
10
A look back at cholangiocarcinoma in Finland.芬兰胆管癌回顾。
United European Gastroenterol J. 2021 Dec;9(10):1103-1104. doi: 10.1002/ueg2.12157. Epub 2021 Sep 28.